Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VLA2001,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Valneva
Deal Size : $39.9 million
Deal Type : Termination
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
Details : VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Product Name : VLA2001
Product Type : Vaccine
Upfront Cash : $35.5 million
September 16, 2022
Lead Product(s) : VLA2001,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Valneva
Deal Size : $39.9 million
Deal Type : Termination
Lead Product(s) : MVA-SARS-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Germany Approves Third Trial of COVID-19 Vaccine Candidate
Details : The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 10, 2020
Lead Product(s) : MVA-SARS-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
